Cell Therapy Production Unit

Milano, Italy

Cell Therapy Production Unit

Milano, Italy
SEARCH FILTERS
Time filter
Source Type

Gaipa G.,San Gerardo Hospital | Gaipa G.,Tettamanti Research Center | Nolli M.L.,NCNbio srl | Vallanti G.,Molmed spa | And 8 more authors.
Cytotherapy | Year: 2016

On November 10, 2014, the representatives of all six certified Good Manufacturing Practices (GMP) cell factories operating in the Lombardy Region of Italy convened a 1-day workshop in Milan titled "Management Models for the Development And Sustainability of Cell Factories: Public-Private Partnership?" The speakers and panelists addressed not only the many scientific, technological and cultural challenges faced by Lombardy Cell Factories, but also the potential impact of advanced therapy medicinal products (ATMPs) on public health and the role played by translational research in this process. Future perspectives for research and development (R&D) and manufacturing processes in the field of regenerative medicine were discussed as well. This report summarizes the most important issues raised by the workshop participants with particular emphasis on strengths and limitations of the R&D and manufacturing processes for innovative therapeutics in Lombardy and what can be improved in this context while maintaining GMP standards. The participants highlighted several strategies to translate patient-specific advanced therapeutics into scaled manufacturing products for clinical application. These included (i) the development of a synergistic interaction between public and private institutions, (ii) better integration with Italian regulatory agencies and (iii) the creation of a network among Lombardy cell factories and other Italian and European institutions. © 2016 International Society for Cellular Therapy.


PubMed | San Gerardo Hospital, Cell Therapy Production Unit, Areta International srl, Cell Factory Fondazione Instituto Of Ricovero E Cura A Carattere Scientifico Ca Granda Ospedale Maggiore Policlinico and 3 more.
Type: Journal Article | Journal: Cytotherapy | Year: 2016

On November 10, 2014, the representatives of all six certified Good Manufacturing Practices (GMP) cell factories operating in the Lombardy Region of Italy convened a 1-day workshop in Milan titled Management Models for the Development And Sustainability of Cell Factories: Public-Private Partnership? The speakers and panelists addressed not only the many scientific, technological and cultural challenges faced by Lombardy Cell Factories, but also the potential impact of advanced therapy medicinal products (ATMPs) on public health and the role played by translational research in this process. Future perspectives for research and development (R&D) and manufacturing processes in the field of regenerative medicine were discussed as well. This report summarizes the most important issues raised by the workshop participants with particular emphasis on strengths and limitations of the R&D and manufacturing processes for innovative therapeutics in Lombardy and what can be improved in this context while maintaining GMP standards. The participants highlighted several strategies to translate patient-specific advanced therapeutics into scaled manufacturing products for clinical application. These included (i) the development of a synergistic interaction between public and private institutions, (ii) better integration with Italian regulatory agencies and (iii) the creation of a network among Lombardy cell factories and other Italian and European institutions.

Loading Cell Therapy Production Unit collaborators
Loading Cell Therapy Production Unit collaborators